Literature DB >> 32793728

Identification of critical genes in gastric cancer to predict prognosis using bioinformatics analysis methods.

Jing Liu1, Liang Ma2, Zhiming Chen1,3, Yao Song4, Tinging Gu1, Xianchen Liu1,3, Hongyu Zhao1,3, Ninghua Yao1,3.   

Abstract

BACKGROUND: Ranking fourth in the world in tumor incidence and second in cancer-related death worldwide, gastric cancer (GC) is one of the major malignant tumors, and has a very complicated pathogenesis. In the present study, we aimed to identify new biomarkers to predict the survival rate of GC patients.
METHODS: The differentially expressed genes (DEGs) between GC tissues and normal stomach tissues were obtained by using GEO2R, and overlapped DEGs were acquired with Venn diagrams. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were conducted with R software. Then, the protein-protein interaction (PPI) of these DEGs was visualized by Cytoscape. Gene Expression Profiling Interactive Analysis (GEPIA) was used to verify the expression differences of hub genes in gastric adenocarcinoma tissues and normal tissues. Overall survival (OS) of hub genes was calculated by Kaplan-Meier plotter.
RESULTS: There were a total of 128 consistently expressed genes in the two datasets: 85 upregulated genes were enriched in extra-cellular matrix (ECM)-receptor interaction, protein digestion and absorption, focal adhesion, gastric acid secretion, mineral absorption, systemic lupus erythematosus, amoebiasis, and PI3K-Akt signaling pathway, and 43 downregulated genes were enriched in palate development, blood coagulation, positive regulation of transcription from RNA polymerase II promoter, axonogenesis, receptor internalization, negative regulation of transcription from RNA polymerase II promoter, and in no significant signaling pathways. From the PPI network analyzed by Molecular Complex Detection (MCODE) plug-in, all 27 upregulated genes were selected. Furthermore, to analyze the OS among these genes, Kaplan-Meier analysis was conducted, and 25 genes were associated with remarkably worse survival. For validation in GEPIA, 11 of 25 genes were discovered to be highly expressed in GC tissues compared to normal OS tissues. Furthermore, in the re-analysis of the Database for Annotation, Visualization and Integrated Discovery (DAVID), three genes [G2/miotic-specific cyclin B1 (CCNB1), polo-like kinases 1 (PLK1), and pituitary tumor-transforming gene-1 (PTTG1)] were markedly enriched in the cell cycle pathway, particulary the G1-G1/S phase.
CONCLUSIONS: Three remarkably upregulated DEGs with poor prognosis in GC were identified and may serve as new prognostic biomarkers and targets in GC therapy. 2020 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Bioinformatical analysis; G2/miotic-specific cyclin B1 (CCNB1); differentially expressed genes (DEGs); gastric cancer (GC); pituitary tumor-transforming gene-1 (PTTG1); polo-like kinases 1 (PLK1); survival

Year:  2020        PMID: 32793728      PMCID: PMC7396774          DOI: 10.21037/atm-20-4427

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  43 in total

Review 1.  Shared and separate functions of polo-like kinases and aurora kinases in cancer.

Authors:  Susanne M A Lens; Emile E Voest; René H Medema
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

2.  [Incidence and mortality of stomach cancer in China, 2013].

Authors:  S W Zhang; Z X Yang; R S Zheng; H M Zeng; W Q Chen; J He
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2017-07-23

3.  Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.

Authors:  Guojun Zhang; Zhe Zhang; Zhuogang Liu
Journal:  Tumour Biol       Date:  2013-03-14

4.  Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data.

Authors:  Nadezhda T Doncheva; John H Morris; Jan Gorodkin; Lars J Jensen
Journal:  J Proteome Res       Date:  2018-12-05       Impact factor: 4.466

5.  Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease.

Authors:  Lucas Kneisel; Klaus Strebhardt; August Bernd; Manfred Wolter; Angelika Binder; Roland Kaufmann
Journal:  J Cutan Pathol       Date:  2002-07       Impact factor: 1.587

Review 6.  Epidemiology of gastric cancer.

Authors:  Katherine D Crew; Alfred I Neugut
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

7.  CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1.

Authors:  Jae-Sung Kim; Eun Ju Kim; Jeong Su Oh; In-Chul Park; Sang-Gu Hwang
Journal:  Cancer Res       Date:  2013-08-27       Impact factor: 12.701

Review 8.  Progress in the treatment of advanced gastric cancer.

Authors:  Zheyu Song; Yuanyu Wu; Jiebing Yang; Dingquan Yang; Xuedong Fang
Journal:  Tumour Biol       Date:  2017-07

9.  Erratum: PLK1 as a potential prognostic marker of gastric cancer through MEK-ER K pathway on PDTX models [Corrigendum].

Authors: 
Journal:  Onco Targets Ther       Date:  2019-01-03       Impact factor: 4.147

10.  Cyclin B1 overexpression in conventional oral squamous cell carcinoma and verrucous carcinoma- A correlation with clinicopathological features.

Authors:  Gururaj B Patil; Kaveri S Hallikeri; Aswini Y Balappanavar; Sudheer G Hongal; P R Sanjaya; Sheetalkumar G Sagari
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-07-01
View more
  2 in total

1.  LINC00200 contributes to the chemoresistance to oxaliplatin of gastric cancer cells via regulating E2F1/RAD51 axis.

Authors:  Mengxin Lin; Meifang Xu; Zongbin Xu; Zongqi Weng; Bingqiang Lin; Yanqin Lan; Qing Liu; Xiaoyan Lin; Jie Pan
Journal:  Hum Cell       Date:  2021-04-06       Impact factor: 4.174

2.  Association of FLG mutation with tumor mutation load and clinical outcomes in patients with gastric cancer.

Authors:  Fu Yicheng; Liu Xin; Yu Tian; Liu Huilin
Journal:  Front Genet       Date:  2022-08-15       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.